Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE Bendamustine with or without rituximab provides an effective and more tolerable alternative to the polytherapy cyclophosphamide–doxorubicin–vincristine–prednisolone (CHOP) in the treatment of haematological tumours and is currently approved for the treatment of many haematological malignancies. Navitoclax (ABT‐263) is a potent inhibitor of Bcl‐2, Bcl‐x L and Bcl‐w, which has demonstrated efficacy in haematological tumours alone and in combination with other agents. This paper describes the in vivo efficacy of combining either bendamustine or bendamustine plus rituximab (BR) with navitoclax in xenograft models of non‐Hodgkin's lymphoma EXPERIMENTAL APPROACH Activity was tested in xenograft models of diffuse large B‐cell lymphoma (DoHH‐2, SuDHL‐4), mantle cell lymphoma (Granta 519) and Burkitt's lymphoma (RAMOS). Activity was also monitored in a systemic model of Granta 519. KEY RESULTS Navitoclax potentiated bendamustine activity in all cell lines tested. Bendamustine activated p53 in Granta 519 tumours, concurrent with activation of caspase 3. Navitoclax also improved responses to bendamustine‐rituximab (BR) in a subset of tumours. CONCLUSIONS AND IMPLICATIONS Navitoclax in combination with bendamustine and BR is a viable combination strategy for use in the clinic and demonstrated superior efficacy compared with previously reported data for navitoclax plus CHOP and rituximab‐CHOP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Self-citationGuidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Cited by
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationMany players in BCL-2 family affairs
Moldoveanu, T., Follis, A. V., Kriwacki, R. W., & Green, D. R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.006 · Cited by 421
“Moreover, these compounds synergize in combination with experimental drugs that cause additional cellular stress and have shown efficacy for a broad spectrum of BCL-2 and BCL-xL–dependent malignancies [85, 86].”
BackgroundABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 281
Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies
Wyld, L., Bellantuono, I., Tchkonia, T., Morgan, J., Turner, O., Foss, F., George, J., Danson, S., & Kirkland, J. L. (2020) · Cancers · doi:10.3390/cancers12082134 · Cited by 235
“2012 [98] In vivo mouse model Bendamustine+Navitoclax ±Rituximab Non-Hodgkins lymphoma Enhanced efficacy in combination”
Cao, D.-S., Jiang, S.-L., Guan, Y.-D., Chen, X.-S., Zhang, L.-X., Zhang, Y., Chen, A. F., Yang, J.-M., & Cheng, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112421 · Cited by 16
Metadata
- Authors
- Ackler, S., Mitten, M., Chen, J., Clarin, J., Foster, K., Jin, S., Phillips, D., Schlessinger, S., Wang, B., Leverson, J., & Boghaert, E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-09-25
- Volume
- 167
- Issue
- 4
- Pages
- 881-891
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1499620539
- Cited by
- 40
- References
- 4
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo. https://app.cochat.ai/papers/10.1111/j.1476-5381.2012.02048.x
- The paper
- Ackler, S., Mitten, M., Chen, J., Clarin, J., Foster, K., Jin, S., Phillips, D., Schlessinger, S., Wang, B., Leverson, J., & Boghaert, E. (2012). Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2012.02048.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.